TheEdgeResearch
Home / Stocks / GLAS

Glass House Brands Inc (GLAS)

NYSE Healthcare Drug Manufacturers - Specialty & Generic
$1.18 ▼ -2.89%
Market Cap
$110.3M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.51
52-Wk Range
1.075-13.19
CEO
Kyle Kazan
Country
US
Currency
USD

Glass House Brands Inc operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Long Beach, CA, US. The stock last traded at $1.18, down 2.89% on the session, giving a market capitalisation of $110.3M. On trailing twelve-month figures it carries a trailing P/E of -1.97, a net margin of -26.7%. Its beta of 0.51 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-1.97
Price / Sales
0.61
Price / Book
0.60
EV / EBITDA
-8.02
Gross margin
31.3%
Operating margin
-20.4%
Net margin
-26.7%
Return on equity
—
Debt / equity
0.38
Current ratio
1.63
Dividend yield
0.0%
Payout ratio
-23.1%
Company profile
Exchange
New York Stock Exchange
Employees
392
IPO date
2026-06-30
Headquarters
Long Beach, CA, US
About Glass House Brands Inc

Glass House Brands, Inc. operates as an integrated cannabis company in the United States with focus on the California market and building brands to serve consumers across various segments. The company is involved in greenhouse cultivation operations, manufacturing practices, brand-building, and retailing activities. The company offers its cannabis products through its portfolio of brands, which includes Glass House Farms, PLUS Products, Allswell, Forbidden Flowers, and Mama Sue Wellness. The company was founded by Kyle Kazan, Graham Farrar and Jocelyn Rosenwald in 2015 and is headquartered in Long Beach, CA.

More research on GLAS
GLAS technical analysis GLAS TheEdge Score Compare against peers
Open full interactive analysis & DCF →